Peripheral Blood MCEMP1 Gene Expression as a Biomarker for Stroke Prognosis

Stroke

Volumn 47, Issue 3, 2016, Pages 652-658

  Raman, Kripa ^a,b   O'Donnell, Martin J ^a,b,e   Czlonkowska, Anna ^f   Duarte, Yan Carlos ^g   Lopez Jaramillo, Patricio ^h,i   Penaherrera, Ernesto ^g   Sharma, Mike ^a,b   Shoamanesh, Ashkan ^a,b   Skowronska, Marta ^f   Yusuf, Salim ^a,c   Pare, Guillaume ^a,d  

^a HAMILTON HEALTH SCIENCES   (Canada)

^b Department of Neurology ^*  (Canada)

^c Clinical Epidemiology and Biostatistics   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^f MEDICAL UNIVERSITY OF WARSAW   (Poland)

^g HOSPITAL LUIS VERNAZA   (Ecuador)

^h Ophthalmological Foundation of Santander   (Colombia)

ⁱ UNIVERSIDAD DE SANTANDER   (Colombia)

Author keywords

Biomarkers; blood; gene expression profiling; prognosis; stroke

Indexed keywords

BIOLOGICAL MARKER; MAST CELL EXPRESSED MEMBRANE PROTEIN 1; PROTEIN; RNA; UNCLASSIFIED DRUG; C19ORF59 PROTEIN, HUMAN; MEMBRANE PROTEIN;

ARTICLE; BLOOD SAMPLING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; DISABILITY; GENE EXPRESSION PROFILING; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; RANKIN SCALE; RISK FACTOR; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; FEMALE; FOLLOW UP; GENETICS; INTERNATIONAL COOPERATION; MALE; PROCEDURES; STROKE;

BIOMARKERS; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HUMANS; INTERNATIONALITY; MALE; MEMBRANE PROTEINS; PROGNOSIS; STROKE;

EID: 84959545368     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.115.011854     Document Type: Article

References (30)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation. 2013;127:e6-e245. doi: 10.1161/CIR.0b013e31828124ad.
2. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet. 2008;371:1612-1623. doi: 10.1016/S0140-6736(08)60694-7.
3. Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al; Stroke Thrombolysis Trialists' Collaborative Group. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014;384:1929-1935. doi: 10.1016/S0140-6736(14)60584-5.
4. Williams JM, Jude MR, Levi CR. Recombinant tissue plasminogen activator (rt-PA) utilisation by rural clinicians in acute ischaemic stroke: a survey of barriers and enablers. Aust J Rural Health. 2013;21:262-267. doi: 10.1111/ajr.12052.
5. Brown DL, Barsan WG, Lisabeth LD, Gallery ME, Morgenstern LB. Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke. Ann Emerg Med. 2005;46:56-60. doi: 10.1016/j.annemergmed.2004.12.025.
6. Scott PA, Xu Z, Meurer WJ, Frederiksen SM, Haan MN, Westfall MW, et al. Attitudes and beliefs of Michigan emergency physicians toward tissue plasminogen activator use in stroke: baseline survey results from the INcreasing Stroke Treatment through INteractive behavioral Change Tactic (INSTINCT) trial hospitals. Stroke. 2010;41:2026-2032. doi: 10.1161/STROKEAHA.110.581942.
7. Dobson MG, Galvin P, Barton DE. Emerging technologies for pointof-care genetic testing. Expert Rev Mol Diagn. 2007;7:359-370. doi: 10.1586/14737159.7.4.359.
8. Tang Y, Lu A, Aronow BJ, Sharp FR. Blood genomic responses differ after stroke, seizures, hypoglycemia, and hypoxia: blood genomic fingerprints of disease. Ann Neurol. 2001;50:699-707.
9. Tang Y, Xu H, Du X, Lit L, Walker W, Lu A, et al. Gene expression in blood changes rapidly in neutrophils and monocytes after ischemic stroke in humans: a microarray study. J Cereb Blood Flow Metab. 2006;26:1089-1102. doi: 10.1038/sj.jcbfm.9600264.
10. Barr TL, Conley Y, Ding J, Dillman A, Warach S, Singleton A, et al. Genomic biomarkers and cellular pathways of ischemic stroke by RNA gene expression profiling. Neurology. 2010;75:1009-1014. doi: 10.1212/WNL.0b013e3181f2b37f.
11. O'Donnell M, Xavier D, Diener C, Sacco R, Lisheng L, Zhang H, et al; INTERSTROKE Investigators. Rationale and design of INTERSTROKE: a global case-control study of risk factors for stroke. Neuroepidemiology. 2010;35:36-44. doi: 10.1159/000306058.
12. O'Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, et al; INTERSTROKE investigators. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376:112-123. doi: 10.1016/S0140-6736(10)60834-3.
13. Shi W, Oshlack A, Smyth GK. Optimizing the noise versus bias trade-off for Illumina whole genome expression BeadChips. Nucleic Acids Res. 2010;38:e204. doi: 10.1093/nar/gkq871.
14. Schmid R, Baum P, Ittrich C, Fundel-Clemens K, Huber W, Brors B, et al. Comparison of normalization methods for Illumina BeadChip HumanHT-12 v3. BMC Genomics. 2010;11:349. doi: 10.1186/1471-2164-11-349.
15. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007;8:118-127. doi: 10.1093/biostatistics/kxj037.
16. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77. doi: 10.1186/1471-2105-12-77.
17. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157-272, discussion 207. doi: 10.1002/sim.2929.
18. Harrel FE Jr. Hmisc: A package of miscellaneous R functions. R package version 3.17-1.
19. 2015. http://CRAN.R-project.org/package=Hmisc. Accessed February 2, 2015.
20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402-408. doi: 10.1006/meth.2001.1262.
21. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. JAMA. 1998;279:1265-1272.
22. Saposnik G, Kapral MK, Liu Y, Hall R, O'Donnell M, Raptis S, et al; Investigators of the Registry of the Canadian Stroke Network; Stroke Outcomes Research Canada (SORCan) Working Group. IScore: a risk score to predict death early after hospitalization for an acute ischemic stroke. Circulation. 2011;123:739-749. doi: 10.1161/CIRCULATIONAHA.110.983353.
23. O'Donnell MJ, Fang J, D'Uva C, Saposnik G, Gould L, McGrath E, et al; Investigators of the Registry of the Canadian Stroke Network. The PLAN score: a bedside prediction rule for death and severe disability following acute ischemic stroke. Arch Intern Med. 2012;172:1548-1556. doi: 10.1001/2013.jamainternmed.30.
24. Adams HP Jr, Davis PH, Leira EC, Chang KC, Bendixen BH, Clarke WR, et al. Baseline NIH Stroke Scale score strongly predicts outcome after stroke: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology. 1999;53:126-131.
25. Li K, Wang SW, Li Y, Martin RE, Li L, Lu M, et al. Identification and expression of a new type II transmembrane protein in human mast cells. Genomics. 2005;86:68-75. doi: 10.1016/j.ygeno.2005.03.006.
26. Andersson S, Nilsson K, Fagerberg L, Hallström BM, Sundström C, Danielsson A, et al. The transcriptomic and proteomic landscapes of bone marrow and secondary lymphoid tissues. PLoS One. 2014;9:e115911. doi: 10.1371/journal.pone.0115911.
27. Strbian D, Karjalainen-Lindsberg ML, Tatlisumak T, Lindsberg PJ. Cerebral mast cells regulate early ischemic brain swelling and neutrophil accumulation. J Cereb Blood Flow Metab. 2006;26:605-612. doi: 10.1038/sj.jcbfm.9600228.
28. Lindsberg PJ, Strbian D, Karjalainen-Lindsberg ML. Mast cells as early responders in the regulation of acute blood-brain barrier changes after cerebral ischemia and hemorrhage. J Cereb Blood Flow Metab. 2010;30:689-702. doi: 10.1038/jcbfm.2009.282.
29. Mattila OS, Strbian D, Saksi J, Pikkarainen TO, Rantanen V, Tatlisumak T, et al. Cerebral mast cells mediate blood-brain barrier disruption in acute experimental ischemic stroke through perivascular gelatinase activation. Stroke. 2011;42:3600-3605. doi: 10.1161/STROKEAHA.111.632224.
30. Oh SH, Kim OJ, Shin DA, Song J, Yoo H, Kim YK, et al. Alteration of immunologic responses on peripheral blood in the acute phase of ischemic stroke: blood genomic profiling study. J Neuroimmunol. 2012;249:60-65. doi: 10.1016/j.jneuroim.2012.04.005.